Compare Bristol-Myers Squibb Co (BMY) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs SYSCO Corporation — how do they compare? Bristol-Myers Squibb Co trades at $58.5 (market cap $116.30B), while SYSCO Corporation trades at $81.82 (market cap $39.62B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.9× SYSCO Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | SYY | |
|---|---|---|
Market Cap | $116.30B | $39.62B |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $91.16 |
52-Week Low | $42.60 | $69.30 |
Enterprise Value | $152.24B | $53.10B |
Dividend Yield | 4.42% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Sysco Corporation (SYY) trades at $83.46, down 0.44% on the day, with a bullish technical signal and positive analyst sentiment. The stock shows strong fundamentals with consistent revenue growth reaching $81.37B in 2025 and a net income margin of 2.08%. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. The company maintains solid cash flow generation and recently announced a $0.55 dividend payable in July 2026.
Sysco's outlook remains favorable with 60% analyst buy ratings and a consensus price target of $83.67, slightly above current levels. Key opportunities include sustained revenue growth and operational efficiencies, while risks involve margin pressure and competitive industry dynamics. The stock presents a balanced investment case with moderate upside potential amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
